WO2024008904 - HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
National phase entry:
Publication Number
WO/2024/008904
Publication Date
11.01.2024
International Application No.
PCT/EP2023/068805
International Filing Date
07.07.2023
Title **
[English]
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
[French]
COMPOSÉS ISVD HAUTEMENT PUISSANTS CAPABLES DE REMPLACER FVIII(A)
Applicants **
NOVO NORDISK A/S
Inventors
VEGGE, Andreas
GRANATA, Daniele
JOHANSSON, Eva
BJELKE, Jais Rose
LUND, Jacob
SASSENE, Philip Jonas
GREISEN, Per, J.
EGEBJERG, Thomas
HUBALEK, Frantisek
FULLE, Simone
NORRMAN, Mathias
BUYSE, Marie-Ange
DE TAVERNIER, Evelyn
STEFFENSEN, Soren
Priority Data
22183825.3
08.07.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3541 | |
| EPO | Filing, Examination, Granting | 20241 | |
| Japan | Filing, Examination, Granting | 2647 | |
| South Korea | Filing, Examination, Granting | 3069 | |
| USA | Filing, Examination, Granting | 19240 |
Total:
48,738
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous- as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.[French]
La présente invention concerne des dérivés de polypeptides ISVD capables de se lier au facteur IX(a) et au facteur X(a) de coagulation qui sont très puissants et fournissent une demi-vie suffisamment longue pour permettre une administration sous-cutanée et perorale efficace. Les dérivés de polypeptides ISVD de l'invention sont ainsi appropriés pour le traitement de l'hémophilie A, de l'hémophilie A avec des inhibiteurs et de l'hémophilie A acquise par diverses voies d'administration comprenant une administration sous-cutanée et perorale.